Pyxis Oncology Inc (PYXS) - Net Assets
Based on the latest financial reports, Pyxis Oncology Inc (PYXS) has net assets worth $68.78 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($105.60 Million) and total liabilities ($36.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PYXS financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $68.78 Million |
| % of Total Assets | 65.13% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 14.09 |
Pyxis Oncology Inc - Net Assets Trend (2019–2024)
This chart illustrates how Pyxis Oncology Inc's net assets have evolved over time, based on quarterly financial data. Also explore PYXS total assets for the complete picture of this company's asset base.
Annual Net Assets for Pyxis Oncology Inc (2019–2024)
The table below shows the annual net assets of Pyxis Oncology Inc from 2019 to 2024. For live valuation and market cap data, see PYXS market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $120.75 Million | -3.94% |
| 2023-12-31 | $125.70 Million | -21.84% |
| 2022-12-31 | $160.82 Million | -38.46% |
| 2021-12-31 | $261.31 Million | +1770.27% |
| 2020-12-31 | $-15.64 Million | -444.36% |
| 2019-12-31 | $-2.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pyxis Oncology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36064100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $60.00K | 0.05% |
| Other Comprehensive Income | $170.00K | 0.14% |
| Other Components | $484.08 Million | 400.89% |
| Total Equity | $120.75 Million | 100.00% |
Pyxis Oncology Inc Competitors by Market Cap
The table below lists competitors of Pyxis Oncology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gowing Bros Ltd
AU:GOW
|
$86.57 Million |
|
Mangold Fondkommission AB
ST:MANG
|
$86.65 Million |
|
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
|
$86.66 Million |
|
Kumpulan Kitacon Berhad
KLSE:5310
|
$86.68 Million |
|
Valuence Merger Corp I
NASDAQ:VMCA
|
$86.52 Million |
|
First US Bancshares Inc
NASDAQ:FUSB
|
$86.50 Million |
|
Graha Layar Prima Tbk
JK:BLTZ
|
$86.49 Million |
|
Freetrailer Group A/S
ST:FREETR
|
$86.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pyxis Oncology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 125,704,000 to 120,751,000, a change of -4,953,000 (-3.9%).
- Net loss of 77,331,000 reduced equity.
- New share issuances of 59,046,000 increased equity.
- Other comprehensive income increased equity by 107,000.
- Other factors increased equity by 13,225,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-77.33 Million | -64.04% |
| Share Issuances | $59.05 Million | +48.9% |
| Other Comprehensive Income | $107.00K | +0.09% |
| Other Changes | $13.22 Million | +10.95% |
| Total Change | $- | -3.94% |
Book Value vs Market Value Analysis
This analysis compares Pyxis Oncology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.83x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.08 | $1.72 | x |
| 2020-12-31 | $-0.46 | $1.72 | x |
| 2021-12-31 | $8.11 | $1.72 | x |
| 2022-12-31 | $4.87 | $1.72 | x |
| 2023-12-31 | $3.15 | $1.72 | x |
| 2024-12-31 | $2.07 | $1.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pyxis Oncology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -64.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -478.95%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.30x
- Recent ROE (-64.04%) is below the historical average (-37.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.38 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.26 Million |
| 2021 | -29.07% | 0.00% | 0.00x | 1.07x | $-102.11 Million |
| 2022 | -73.34% | 0.00% | 0.00x | 1.31x | $-134.04 Million |
| 2023 | -58.70% | 0.00% | 0.00x | 1.38x | $-86.36 Million |
| 2024 | -64.04% | -478.95% | 0.10x | 1.30x | $-89.41 Million |
Industry Comparison
This section compares Pyxis Oncology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pyxis Oncology Inc (PYXS) | $68.78 Million | 0.00% | 0.54x | $86.55 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candida… Read more